Molecular biology of vestibular schwannomas.
Recent advances in molecular biology have led to a better understanding of the etiology of vestibular schwannomas. The underlying purpose of vestibular schwannoma research is the development of new treatment options; however, such options have not yet been established. A fundamental understanding of the underlying molecular events leading to tumor formation began when mutations in the neurofibromatosis type 2 (NF2) tumor suppressor gene were identified in vestibular schwannomas. The clinical characteristics of vestibular schwannomas and neurofibromatosis type 2 (NF2) syndromes have both been related to alterations in the NF2 gene. Genetic screening for NF2 is now available. When utilized with clinical screening, such as magnetic resonance imaging (MRI), conventional audiometry, and auditory brainstem response (ABR), the early detection of NF2 can be made, which consequently makes a significant difference in the ability to successfully treat vestibular schwannomas. Additionally, the signaling pathways affected by merlin, the product of the NF2 gene, are becoming better understood. Nf2-transgenic and knockout mice as well as vestibular schwannoma xenograft models are now ready for novel therapeutic testing. Hopefully, better treatment options will be forthcoming soon.
Chang
Long-Sheng
LS
Department of Pediatrics, The Ohio State University College of Medicine, Center for Childhood Cancer Research Institute at National Childen's Hospital, Columbus, OH, USA.
Welling
D Bradley
DB
D000818:Animals; D004252:DNA Mutational Analysis; D020022:Genetic Predisposition to Disease; D006801:Humans; D008279:Magnetic Resonance Imaging; D051379:Mice; D018345:Mice, Knockout; D016513:Mice, SCID; D008822:Mice, Transgenic; D009154:Mutation; D016518:Neurofibromatosis 2 / Q000235:genetics / Q000473:pathology; D025581:Neurofibromin 2 / Q000235:genetics*; D009464:Neuroma, Acoustic / Q000235:genetics* / Q000473:pathology
D025581:Neurofibromin 2